The widened net loss is not reflective of operational deterioration but a non-cash accounting item. The improved cash runway and upcoming clinical catalysts (GTB-5550 initiation, Q3 2026 data update) may support investor sentiment, but the small market cap ($13M) and history of losses suggest high risk. Monitor for future funding needs and clinical data.
Price Chart
Executive Summary
GT Biopharma reported its 2025 financial results, showing reduced R&D and operating losses but a sharply higher net loss due to a $15.2M non-cash charge tied to preferred stock valuation. The company has $7M in cash as of year-end 2025, with a proforma balance of $9M in January 2026, funding operations through Q4 2026. Clinical progress includes ongoing GTB-3650 enrollment and FDA clearance for GTB-5550, with a trial expected to start mid-2026.
Key Facts
- Cash and cash equivalents: $7M as of December 31, 2025; unaudited proforma cash of $9M as of January 31, 2026
- Net loss: $28.4M in 2025 vs. $13.2M in 2024, driven by a $15.2M non-cash expense from preferred stock valuation
- R&D expenses decreased to $3.5M from $5.8M due to lower production costs
- Loss from operations improved to $12.4M from $14.4M
- SG&A expenses flat at ~$8.5M
- GTB-3650 Phase 1 trial ongoing, with Cohort 5 (25 µg/kg/day) expected to start in Q2 2026; next data update expected Q3 2026
- FDA cleared IND for GTB-5550 in January 2026; Phase 1 basket trial expected to initiate mid-2026
Financial Impact
Net loss widened by $15.2M due to non-cash charge; operating loss improved by $2M. Cash runway extended to Q4 2026 with $9M proforma balance.
Risk Factors
- Company faces going concern risk as noted in forward-looking statements
- High net loss despite lower operating expenses due to non-cash items may concern investors
- Need for future capital raises could lead to dilution
- Clinical trial delays could impact timeline and funding runway
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247203 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $9.00 $7.16 | ▲ +20.44% | ▲ +21.26% | $6.18 (+31.39%) |
Sep 3, 2026 29d ago | 8-K | $0.2524 $8.61 | ▲ +3311.25% | ▲ +3312.40% | $6.18 (+2346.51%) |
Aug 14, 2026 7w ago | Press Release | $0.2960 $0.2886 | ▲ +2.50% | ▲ +1.13% | $6.18 (−1986.15%) |
May 22, 2026 19w ago | 8-K | $0.4400 $0.4420 | ▼ −0.45% | ▲ +1.22% | $6.18 (−1303.41%) |
Apr 30, 2026 22w ago | S-1 | $0.3430 $0.3750 | ▼ −9.33% | ▼ −6.98% | $6.18 (−1700.29%) |
Apr 7, 2026 25w ago | 8-K | $0.4130 $0.3890 | ▼ −5.81% | ▼ −11.14% | $6.18 (+1395.16%) |
Mar 2, 2026 30w ago | Press Release | $0.4670 $0.4170 | ▼ −10.71% | ▼ −9.50% | $6.18 (+1222.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access